Elite Clinical Network Announces The Appointment Of Christopher Brennan As Chief Executive Officer

Elite Clinical Network (ECN), a fully-integrated clinical research site network, has appointed Christopher Brennan as its new Chief Executive Officer. With more than 25 years of leadership experience in pharmaceutical services and drug development, Chris Brennan brings extensive industry expertise that will support ECN’s strategy to expand both its clinical capabilities and its network of research sites.

Throughout his career, Chris has held senior executive positions at a range of large and mid-sized Contract Research Organizations (CROs), including inVentiv (now Syneos Health). He has also worked with companies focused on clinical trial enablement, such as Bioclinica (now Clario), where he contributed to solutions in medical imaging, trial management, and patient recruitment.

Chris Brennan said in a statement, “I am humbled to assume the position of Chief Executive Officer at ECN. To have the opportunity to lead such a talented management team as we work relentlessly and methodically to realize ECN’s full potential is a privilege. Chip Gillooly (as Operating Partner) and John Giammona, Ph.D. (as Chief Growth Officer) recently joined ECN, bolstering an already highly capable leadership team. With this team, along with ECN’s robust principal investigator corps and dedicated site staff across our expansive site network, I am confident that ECN’s role as a critical partner to pharmaceutical companies and CROs will continue to expand. Most importantly, I am certain that as ECN’s capabilities grow and gain efficiencies, we will be able to help bring even more life-changing therapies to the clinical trial patients that ECN staff members care for every day.”

Sanjay Gulati, Principal at Surge Private Equity, said in a statement, “After a comprehensive search led by David Wilson III and me, we are both thrilled that Chris is assuming the role of ECN’s Chief Executive Officer.  His proven track record of leading multi-disciplinary teams to successful outcomes on a variety of ‘mission critical’ corporate opportunities, as well as his ‘DNA match’ to the ECN team give us great confidence that Chris, along with his management team, will propel ECN to the next level.”

Most recently, Chris served as Chief Operating Officer at Allucent, a mid-sized CRO. During his nearly six-year tenure, he led the company’s transformation from a 200-person, regionally focused organization into a global company with 1,200 employees. In addition to managing this growth, he oversaw multiple business units and played a key role in integrating operations across geographies.

With Chris Brennan stepping into the role of CEO, ECN is reinforcing its commitment to building a strong leadership team to support its growth and further establish its position in the clinical research space. The company aims to play a more prominent role in the expanding clinical site network sector, which is becoming increasingly vital in clinical trial execution for both pharmaceutical sponsors and CROs.